Headache is NOT a Common Side Effect of Mounjaro (Tirzepatide)
Headache is not listed among the common adverse effects of Mounjaro (tirzepatide), which occur in ≥5% of patients. The FDA-approved drug label specifically identifies the most common adverse reactions as nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain—notably, headache is absent from this list 1.
What the Evidence Shows
Official FDA Data
The FDA prescribing information for Mounjaro clearly delineates adverse reactions occurring in ≥5% of treated patients, and headache does not meet this threshold 1. This represents the highest quality regulatory evidence available.
Clinical Trial and Real-World Data
Recent systematic reviews and meta-analyses confirm this pattern:
A 2025 meta-analysis of 12 randomized controlled trials involving 10,615 patients with type 2 diabetes found no statistically significant increase in headache risk with tirzepatide (RR 1.00,95% CI 0.65 to 1.55) 2
A 2025 social media surveillance study analyzing 64,202 Facebook posts about GLP-1 RA medications found headache mentioned in only 1.86% of tirzepatide-related posts 3
Multiple 2025 clinical practice guidelines from the American Association of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism extensively detail tirzepatide's side effect profile, consistently emphasizing gastrointestinal symptoms as the predominant adverse effects while not highlighting headache as a concern 4, 5, 4
The Actual Common Side Effects
The gastrointestinal side effects are what patients should expect, occurring most frequently during dose escalation 5:
- Nausea (most common, affecting approximately 25% of GLP-1 RA users)
- Diarrhea (up to 10%)
- Vomiting (up to 10%)
- Decreased appetite
- Constipation
- Dyspepsia
- Abdominal pain
These gastrointestinal effects are typically transient and can be mitigated through slow dose titration, eating smaller meals, avoiding fatty or spicy foods, and staying well-hydrated 4, 5, 4.
Important Clinical Caveats
While headache is not a common side effect, there are two noteworthy considerations:
Dizziness IS increased: A 2025 meta-analysis found tirzepatide significantly increased dizziness risk (RR 1.64,95% CI 1.04 to 2.57), particularly in patients ≤60 years old 2. Patients reporting "headache" may actually be experiencing dizziness.
Individual variation exists: The absence of headache from common side effect lists doesn't mean it never occurs—just that it affects fewer than 5% of patients and occurs at rates similar to placebo.
If a patient on Mounjaro develops persistent or severe headaches, consider alternative etiologies rather than automatically attributing them to the medication, including dehydration from gastrointestinal side effects, changes in blood glucose, or unrelated conditions.